Skip to content

Study · Animal study (in vivo) · rat · 2018

3 results

An endogeous defensive concept, renewed cytoprotection/adaptive cytoprotection: intra(per)-oral/intragastric strong alcohol in rat. Involvement of pentadecapeptide BPC 157 and nitric oxide system.

Becejac T, Cesarec V, Drmic D, Hirsl D, Madzarac G, Djakovic Z, Bunjevac I, A Zenko Sever A, Sepac A, Batelja Vuletic L, Stancic Rokotov D, Seiwerth S, Sikiric P

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society1 Jun 2018Cited by 13 (Europe PMC)

PMID30279308 (opens in a new tab)DOI10.26402/jpp.2018.3.11 (opens in a new tab)PepBankPUB-30279308
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with strong alcohol lesions, BPC‑157 given intraperitoneally after the alcohol apparently cured all of the alcohol lesions.

    In plain wordsIn rats with alcohol-induced lesions, BPC‑157 appeared to cure the lesions.

    Peptide
    BPC-157
    Outcome
    DecreaseAlcohol-induced lesions in stomach, tongue, esophagus and duodenum
    Study

    ratn: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.01 and 0.00001 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 apparently cured all alcohol-lesions
    1 context sentence
    Summary · context
    Immediate post-alcohol intraperitoneal medication (mg/kg) was the stable gastric pentadecapeptide BPC 157 (0.01, 0.00001; a Robert's cytoprotection mediator; with a therapeutic effect), NOS-blocker L-NAME (5), and NOS-substrate L-arginine (100 mg), (NO-system involvement).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given strong alcohol, BPC‑157 amplified the spontaneously initiated beneficial effect on the mucosa.

    In plain wordsIn rats given strong alcohol, BPC‑157 strengthened the protective effect on the gut lining.

    Peptide
    BPC-157
    Outcome
    IncreaseMucosal protection after alcohol
    Study

    ratn: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.01 and 0.00001 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    amplified the spontaneously initiated strong mucosal beneficial effect
    1 context sentence
    Summary · context
    Immediate post-alcohol intraperitoneal medication (mg/kg) was the stable gastric pentadecapeptide BPC 157 (0.01, 0.00001; a Robert's cytoprotection mediator; with a therapeutic effect), NOS-blocker L-NAME (5), and NOS-substrate L-arginine (100 mg), (NO-system involvement).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given strong alcohol, BPC‑157 rescued the lowered sphincter pressures.

    In plain wordsIn rats given strong alcohol, BPC‑157 restored the lowered sphincter pressures.

    Peptide
    BPC-157
    Outcome
    IncreaseLower esophageal and pyloric sphincter pressure
    Study

    ratn: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.01 and 0.00001 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    rescued sphincter pressures
    1 context sentence
    Summary · context
    Immediate post-alcohol intraperitoneal medication (mg/kg) was the stable gastric pentadecapeptide BPC 157 (0.01, 0.00001; a Robert's cytoprotection mediator; with a therapeutic effect), NOS-blocker L-NAME (5), and NOS-substrate L-arginine (100 mg), (NO-system involvement).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.